Proposition 14 is on the California ballot to continue funding stem cell research by borrowing up to $5.5 billion through bonds.

CALIFORNIA, USA California Proposition 14 is a vote to approve $5.5 billion dollars for stem cell research and research facilities in the state. In 2004, California voters approved Proposition 71. It gave legal protection to stem cell research that was hoping to find new medical treatments or cures for everything from Parkinsons to cancer. Proposition 71 also approved spending more than $3 billion to use for stem cell research and to build research facilities. Since 2004, most of the funding has been spent.

Proposition 14 would help to continue the funding of the existing research program with an additional $5.5 billion. The total estimated cost of the bond is an additional $260 million per year for the next 30 years. The total cost to pay off the bond is estimated to be $7.8 billion ($5.5 billion in bonds + $2.3 billion in interest).

Proposition 14 does offer a chance for the state to make back some money, a unique property compared to most state bonds. If the research leads to new inventions that earn revenue, the state will get a portion of the profits.

So far thats only raised about $350,000 or about 0.01% of the bond money weve already spent on stem cell work since 2004.

Find more background about this proposition as well as opinions from both sides on the California Voter Guide or on your local voter guide.

What is the full name for Prop 14?

The California Stem Cell Research, Treatments, and Cures Initiative of 2020

What does a YES vote on Prop 14 mean?

A yes vote approves $5.5 billion dollars for stem cell research and research facilities. The money will come from a bond.

What does a NO vote on Prop 14 mean?

A no vote means that the states existing stem cell program would start to wind down.

Original filing for Prop 14

Visit link:
CA Prop 14: Stem cell research - CBS News 8

Cellnest was designed and manufactured by Fujifilm Corporation.

Fujifilm sold cellnest through other company channels previously. However, Fujifilm Irvine Scientific is best placed to sell these products since they are complementary to our portfolio of cell culture media for primary cells. We joined Fujifilm in 2018 and synergies such as this are part of the Fujifilm life science strategy, said Lori Serles, spokesperson, Fujifilm Irvine Scientific.

Attachment substrates mimic the extracellular matrix (ECM), a complex and dynamic environment in which cells reside in vivo, in cell culture and allow for the adhesion, expansion, and potential differentiation of stem cells.

Unlike animal-derived components, which can introduce unpredictability in results, the chemically defined, animal component-free formula of cellnest provides consistent results to researchers and can smooth the regulatory path to commercialization, claims Fujifilm Irvine Scientific.

Serles expanded on how those aspects, highlighting that natural and undefined components present regulatory and production concerns.

There is considerable quantitative and qualitative variability in the composition of serum and serumderived products such as HSA. Levels of key growth factors, hormone, etc. can vary widely.

The components in media and the culture system affect attachment, growth, differentiation, phenotype etc. Ultimately that produces variability in in the culture system. While that might not be critical in early research, for translational and clinical research reliable results are necessary.

Regulatory bodies want to mitigate risk. Using a defined substrate in the culture system reduces the risk of variability in the end treatment/efficacy of the therapy. It also reduces risk of adventitious agents entering the process, she told BioPharma-Reporter.

What type of cell or gene therapy research will the use of this substrate help advance?

"Cellnest will contribute to advancing cell therapies involving human mesenchymal stem cells (hMSC).The cell and gene therapy market is maturing and the number of therapies progressing to clinical research phases is increasing rapidly. By providing defined and chemically defined products that can contribute to reliable, consistent results in culture systems, we are supporting this maturation.More therapeutic uses for hMSCs are being discovered, including new clinical trials for the treatment of coronavirus-induced disease, said Serles.

Cellnest is compatible with any adherent cell type that binds to the Arg-Gly-Asp (RGD) domain, an amino acid sequence within the extracellular matrix protein fibronectin that mediates cell attachment, said the producer.

See the original post:
Fujifilm Irvine Scientific takes on distribution of substrate that supports cell therapy research - BioPharma-Reporter.com

DUBLIN, Sept. 30, 2020 /PRNewswire/ -- The "Global Regenerative Medicine Partnering Terms and Agreements 2014 to 2020" report has been added to ResearchAndMarkets.com's offering.

The Global Regenerative Medicine Partnering Terms and Agreements 2014-2020 report provides comprehensive understanding and unprecedented access to the regenerative medicine including cell therapy, organ regeneration, stem cells and tissue regeneration partnering deals and agreements entered into by the worlds leading healthcare companies.

The report provides a detailed understanding and analysis of how and why companies enter Regenerative Medicine partnering deals. These deals tend to be multicomponent, starting with collaborative R&D, and proceed to commercialization of outcomes.

This report provides details of the latest Regenerative Medicine agreements announced in the life sciences since 2014.

The report takes the reader through a comprehensive review Regenerative Medicine deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering Regenerative Medicine partnering deals.

The report presents financial deal term values for Regenerative Medicine deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the Regenerative Medicine partnering field; both the leading deal values and most active Regenerative Medicine dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

One of the key highlights of the report is that over 1100 online deal records of actual Regenerative Medicine deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via Weblink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

A comprehensive series of appendices is provided organized by Regenerative Medicine partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in Regenerative Medicine partnering and dealmaking since 2014.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of Regenerative Medicine technologies and products.

Key benefits

Global Regenerative Medicine Partnering Terms and Agreements 2014-2020 provides the reader with the following key benefits:

In Global Regenerative Medicine Partnering Terms and Agreements 2014-2020, the available deals are listed by:

Key Topics Covered:

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in Regenerative Medicine dealmaking2.1. Introduction2.2. Regenerative Medicine partnering over the years2.3. Most active Regenerative Medicine dealmakers2.4. Regenerative Medicine partnering by deal type2.5. Regenerative Medicine partnering by therapy area2.6. Deal terms for Regenerative Medicine partnering2.6.1 Regenerative Medicine partnering headline values2.6.2 Regenerative Medicine deal upfront payments72.6.3 Regenerative Medicine deal milestone payments2.6.4 Regenerative Medicine royalty rates

Chapter 3 - Leading Regenerative Medicine deals3.1. Introduction3.2. Top Regenerative Medicine deals by value

Chapter 4 - Most active Regenerative Medicine dealmakers4.1. Introduction4.2. Most active Regenerative Medicine dealmakers4.3. Most active Regenerative Medicine partnering company profiles

Chapter 5 - Regenerative Medicine contracts dealmaking directory5.1. Introduction5.2. Regenerative Medicine contracts dealmaking directory

Chapter 6 - Regenerative Medicine dealmaking by technology type

Chapter 7 - Partnering resource center7.1. Online partnering7.2. Partnering events7.3. Further reading on dealmaking

AppendicesAppendix 1 - Regenerative Medicine deals by company A-ZAppendix 2 - Regenerative Medicine deals by stage of developmentAppendix 3 - Regenerative Medicine deals by deal typeAppendix 4 - Regenerative Medicine deals by therapy area

For more information about this report visit https://www.researchandmarkets.com/r/dcq9uu

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager [emailprotected]

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Read the original:
Global Regenerative Medicine Partnering Report 2014-2020: Access to Cell Therapy, Organ Regeneration, Stem Cells and Tissue Regeneration Partnering...

Global Adipose Derived Stem Cell Therapy Market 2020 by Company, Type and Application, Forecast to 2025 is the latest addition to the database of MarketsandResearch.biz which exhibits an easily comprehensible description of the global market. The report provides proficient and in-depth research on the market, focusing on the market landscape and its growth prospects over the coming years from 2020 to 2025. The report emphasizes market share, market demographics, size as well as valuation and voluminous growth rate. The research also includes a discussion of the key vendors operating in this global Adipose Derived Stem Cell Therapy market. The study shares details such as current trends of the market in conjunction with the geographical landscape, demand scope, remuneration scale, and growth graph of this vertical have also been included in this report.

The report covers an in-depth analysis of the key trends and emerging drivers of the market as well as market characteristics, competitive landscape, market size and growth, regional breakdown, and strategies for this market. The research analyzes revenue growth, product range, and pricing factors related to the global Adipose Derived Stem Cell Therapy market. The report sheds light on the competition matrix and shares a versatile understanding of various vital details comprising new product related developments that are adequately addressed and invested by leading players in the global market. Details about the competitive landscape, ensuring robust growth in the global market has been given in the report.

NOTE: Our analysts monitoring the situation across the globe explains that the market will generate remunerative prospects for producers post COVID-19 crisis. The report aims to provide an additional illustration of the latest scenario, economic slowdown, and COVID-19 impact on the overall industry.

DOWNLOAD FREE SAMPLE REPORT: https://www.marketsandresearch.biz/sample-request/89396

The major players covered in the market are: AlloCure, Mesoblast, Cellleris, Antria, Intrexon, Celgene Corporation, Tissue Genesis, Cytori Therapeutics, Corestem, Pluristem Therapeutics, Cyagen, BioRestorative Therapies, Lonza, Pluristem Therapeutics, Celltex Therapeutics Corporation, iXCells Biotechnologies

Scope of Market Report:

This report provides an analysis of the supply chain, import, and export control, and future influence on the industry. Detailed analysis of the market status, competition pattern, advantages, and disadvantages of enterprise products, industry development trends (2020-2025), regional industrial layout characteristics, industrial policy has also been included. From raw materials to end-users of this industry are analyzed, as well as the trends of product circulation and sales channels are presented.

On the basis of regional segmentation, the market is bifurcated into major regions of North America (United States, Canada and Mexico), Europe (Germany, France, UK, Russia and Italy), Asia-Pacific (China, Japan, Korea, India and Southeast Asia), South America (Brazil, Argentina, etc.), Middle East & Africa (Saudi Arabia, Egypt, Nigeria and South Africa). The regional analysis further covers country-wise bifurcation of the market and key players.

On the basis of product type, we research the production, revenue, price, market share, and growth rate, primarily split into: Autologous Stem Cells, Allogeneic Stem Cells

For the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate of Adipose Derived Stem Cell Therapy market report for each application, including: Therapeutic Application, Research Application

ACCESS FULL REPORT: https://www.marketsandresearch.biz/report/89396/global-adipose-derived-stem-cell-therapy-market-2020-by-company-type-and-application-forecast-to-2025

Unraveling Report Offerings

Customization of the Report:

This report can be customized to meet the clients requirements. Please connect with our sales team ([emailprotected]), who will ensure that you get a report that suits your needs. You can also get in touch with our executives on +1-201-465-4211 to share your research requirements.

About Us

Marketsandresearch.biz is a leading global Market Research agency providing expert research solutions, trusted by the best. We understand the importance of knowing what global consumers watch and buy, further using the same to document our distinguished research reports. Marketsandresearch.biz has worldwide presence to facilitate real market intelligence using latest methodology, best-in-class research techniques and cost-effective measures for worlds leading research professionals and agencies. We study consumers in more than 100 countries to give you the most complete view of trends and habits worldwide. Marketsandresearch.biz is a leading provider of Full-Service Research, Global Project Management, Market Research Operations and Online Panel Services.

Contact UsMark StoneHead of Business DevelopmentPhone: +1-201-465-4211Email: [emailprotected]Web: http://www.marketsandresearch.biz

The rest is here:
Global Adipose Derived Stem Cell Therapy Market 2020 Industry Analysis, Growth Factors, Share, Opportunities and Forecast to 2025 - The Daily...

Researchers at Cima and the Clinica Universidad de Navarra (Spain) have led an international study identifying the cardiac cells responsible for repairing the damage to this organ after infarction. These "restorative" cells are a subpopulation of cardiac fibroblasts that play a fundamental role in the creation of the collagen scar needed to avoid the rupture of the ventricular wall. The research also reveals the molecular mechanisms involved in the activation of these cells and the regulation of their function.

This finding, in which basic and clinical researchers have participated, will permit the identification of new therapeutic targets and the development of targeted therapies which will control the healing process of the heart after infarction.

The study has been published in the latest issue of the journal Circulation, the leading scientific journal of the American Heart Association.Characterization of the reparative cardiac fibroblasts

Cardiac fibroblasts are one of the fundamental components of the heart. These cells play an essential role in maintaining the structure and mechanism of this vital organ. "Recent studies have shown that fibroblasts do not respond homogeneously to heart injury. Therefore the object of our study was to determine their heterogeneity during the remodeling of the injured ventricle and to understand the mechanisms that regulate the function of these cells", said Dr Felipe Prsper, a researcher at Cima and the Clinica Universidad de Navarra, the leader of the study.

"Using single-cell transcription analysis techniques (single-cell RNA-seq), we identified a subpopulation within the cardiac fibroblasts, which we have named Reparative Cardiac Fibroblasts (RCF) due to their role after the cardiac injury. We have found that, when a patient has a heart attack, these RCF are activated and offer a fibrotic response due to which a collagen scar is generated to avoid the rupture of the cardiac tissue", stated Dr Prsper, who is also a member of the Red de Terapia Celular (TerCel) and the Instituto de Investigacin Sanitaria de Navarra (IdiSNA).

CTHRC1, a protein related to collagen and essential for the regenerative process

In the detailed molecular study, the researchers have found that the RCF have a unique transcriptional profile, that is to say, a specific information pattern for the expression of the genes involved in their cardiac function. "Among the main differential markers of the transcriptome of these cells, we have identified the CTHRC1 protein (Collagen Triple Helix Repeat Containing 1), a molecule with a fundamental role in the fibrotic response after myocardial infarction. Specifically, this protein participates in the collagen synthesis of the extracellular cardiac matrix and is crucial for the process of ventricular remodeling", in the words of Adrin Ruiz-Villalba, a researcher on the Regenerative Medicine Program at Cima and first author of the article.

These results "suggest that the RCF activates the healing scar process of the cardiac lesion by secreting the CTHRC1 protein. Thus, this molecule may be considered as a biomarker associated with the physiological condition of the injured heart and a potential therapeutic target for patients who have suffered a heart attack or have dilated cardiomyopathy", stated Ruiz-Villalba, who is also a researcher at IdiSNA. In addition to Cima and the Clinica Universidad de Navarra, basic and clinical researchers from the United States, Belgium and Austria have taken part in this research.

This work falls within the framework of the Cell Therapy and Regenerative Medicine research line being carried out at Cima and the Clinica Universidad de Navarra, aimed at understanding the regenerative potential of stem cells and their therapeutic application in different diseases such as cardiovascular ones. Specifically, this study is linked to the BRAV? project, an international research project combining bioengineering and cardiac stem cells to restore the function of an infarcted heart. BRAV? is an H2020 funded program by the European Union (H2020-SC1-BHC-07-2019-874827).

Reference: Ruiz-Villalba A, Romero JP, Hernandez SC, et al.Single-Cell RNA-seq Analysis Reveals a Crucial Role for Collagen Triple Helix Repeat Containing 1 (CTHRC1) Cardiac Fibroblasts after Myocardial Infarction. Circ, 2020. doi:10.1161/CIRCULATIONAHA.119.044557

This article has been republished from the following materials. Note: material may have been edited for length and content. For further information, please contact the cited source.

More here:
Researchers Discover Cells That Heal Cardiac Damage After Infarction - Technology Networks

Fort Collins, Colorado The STEM CELL BANKING Market is growing at a rapid pace and contributes significantly to the global economy in terms of turnover, growth rate, sales, market share and size. The STEM CELL BANKING Market Report is a comprehensive research paper that provides readers with valuable information to understand the basics of the STEM CELL BANKING Report. The report describes business strategies, market needs, dominant market players and a futuristic view of the market.

The report has been updated to reflect the most recent economic scenario and market size regarding the ongoing COVID-19 pandemic. The report looks at the growth outlook as well as current and futuristic earnings expectations in a post-COVID scenario. The report also covers changing market trends and dynamics as a result of the pandemic and provides an accurate analysis of the impact of the crisis on the market as a whole.

Global STEM CELL BANKING Market to reach USD 11.2 billion by 2025. Global STEM CELL BANKING Market valued approximately USD 5.4 billion in 2016 is anticipated to grow with a healthy growth rate of more than 8.4% over the forecast period 2017-2025.

Get a sample of the report @ https://reportsglobe.com/download-sample/?rid=5214

Industry STEM CELL BANKING Study provides an in-depth analysis of key market drivers, opportunities, challenges and their impact on market performance. The report also highlights technological advancements and product developments that drive market needs.

The report contains a detailed analysis of the major players in the market, as well as their business overview, expansion plans and strategies. Key players explored in the report include:

The report provides comprehensive analysis in an organized manner in the form of tables, graphs, charts, pictures and diagrams. Organized data paves the way for research and exploration of current and future market outlooks.

Request a Discount on the report @ https://reportsglobe.com/ask-for-discount/?rid=5214

The report provides comprehensive data on the STEM CELL BANKING market and its trends to help the reader formulate solutions to accelerate business growth. The report provides a comprehensive overview of the economic scenario of the market, as well as its benefits and limitations.

The STEM CELL BANKING Market Report includes production chain analysis and value chain analysis to provide a comprehensive picture of the STEM CELL BANKING market. The research consists of market analysis and detailed analysis of application segments, product types, market size, growth rates, and current and emerging industry trends.

By Application:

Request customization of the report @https://reportsglobe.com/need-customization/?rid=5214

The market is geographically spread across several key geographic regions and the report includes regional analysis as well as production, consumption, revenue and market share in these regions for the 2020-2027 forecast period. Regions include North America, Latin America, Europe, Asia Pacific, the Middle East, and Africa.

Radical Coverage of the STEM CELL BANKING Market:

Key Questions Addressed in the Report:

To learn more about the report, visit @ https://reportsglobe.com/product/global-stem-cell-banking-market-size-study/

Thanks for reading our report. It is possible to adapt this report to the wishes of the customer. Contact us to learn more about the report and our team will make sure you create a report based on your needs.

How Reports Globe is different than other Market Research Providers

The inception of Reports Globe has been backed by providing clients with a holistic view of market conditions and future possibilities/opportunities to reap maximum profits out of their businesses and assist in decision making. Our team of in-house analysts and consultants works tirelessly to understand your needs and suggest the best possible solutions to fulfill your research requirements.

Our team at Reports Globe follows a rigorous process of data validation, which allows us to publish reports from publishers with minimum or no deviations. Reports Globe collects, segregates, and publishes more than 500 reports annually that cater to products and services across numerous domains.

Contact us:

Mr. Mark Willams

Account Manager

US: +1-970-672-0390

Email:[emailprotected]

Web:reportsglobe.com

View post:
STEM CELL BANKING Market Potential Growth, Size, Share, Demand and Analysis of Key Players Research Forecasts to 2027 - The Daily Chronicle